Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients

다국어 초록 (Multilingual Abstract)

Purpose: The p53 gene is one of the most frequently mutatedgenes in breast cancer. We investigated the patterns and biologicfeatures of p53 gene mutation and evaluated their clinical significancein Korean breast cancer patients. Methods: Patients whounderwent p53 gene sequencing were included. Mutational analysisof exon 5 to exon 9 of the p53 gene was carried out usingpolymerase chain reaction-denaturing high performance liquidchromatography and direct sequencing. Results: A total of 497patients were eligible for the present study and p53 gene mutationswere detected in 71 cases (14.3%). Mutation of p53 wassignificantly associated with histologic grading (p<0.001), estrogenreceptor and progesterone receptor status (p<0.001), HER2status (p<0.001), Ki-67 (p=0.028), and tumor size (p=0.004).
The most frequent location of p53 mutations was exon 7 andmissense mutation was the most common type of mutation.
Compared with patients without mutation, there was a statisticallysignificant difference in relapse-free survival of patients withp53 gene mutation and missense mutation (p=0.020, p=0.006,respectively). Only p53 missense mutation was an independentprognostic factor for relapse-free survival in multivariate analysis,with an adjusted hazard ratio of 2.29 (95% confidence interval,1.08–4.89, p=0.031). Conclusion: Mutation of the p53 gene wasassociated with more aggressive clinicopathologic characteristicsand p53 missense mutation was an independent negativeprognostic factor in Korean breast cancer patients.

참고문헌 (Reference)

1 Yonish-Rouach E, "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6" 352 : 345-347, 1991

2 Levrero M, "The p53/p63/p73 family of transcription factors: overlapping and distinct functions" 113 (113): 1661-1670, 2000

3 Levine AJ, "The p53 tumour suppressor gene" 351 : 453-456, 1991

4 Curtis C, "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups" 486 : 346-352, 2012

5 Bull SB, "The combination of p53 mutation and neu/erbB-2amplification is associated with poor survival in node-negative breast cancer" 22 : 86-96, 2004

6 Olivier M, "The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer" 12 : 1157-1167, 2006

7 Olivier M, "TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis" 11 : 353-360, 2001

8 Børresen-Dale AL, "TP53 and breast cancer" 21 : 292-300, 2003

9 Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" 22 : 1736-1747, 2011

10 Pharoah PD, "Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis" 80 : 1968-1973, 1999

11 Rakha EA, "Prognostic markers in triple-negative breast cancer" 109 : 25-32, 2007

12 Végran F, "Only missense mutations affecting the DNA binding domain of p53influence outcomes in patients with breast carcinoma" 8 : e55103-, 2013

13 Berns EM, "Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer" 77 : 1130-1136, 1998

14 Perou CM, "Molecular portraits of human breast tumours" 406 : 747-752, 2000

15 Kaplan HG, "Impact of triple negative phenotype on breast cancer prognosis" 14 : 456-463, 2008

16 Grann VR, "Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma" 103 : 2241-2251, 2005

17 Alsner J, "Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients" 6 : 3923-3931, 2000

18 Xiao W, "Denaturing high-performance liquid chromatography:a review" 17 : 439-474, 2001

19 Keller G, "Denaturing high pressure liquid chromatography (DHPLC) for the analysis of somatic p53 mutations" 81 : 1735-1737, 2001

20 Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours" 490 : 61-70, 2012

21 Berns EM, "Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer" 60 : 2155-2162, 2000

22 Sotiriou C, "Breast cancer classification and prognosis based on gene expression profiles from a population-based study" 100 : 10393-10398, 2003

23 Edge S, "AJCC Cancer Staging Manual" Springer 2010